Drugs / T-Cell Therapy
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07374029 | Feb 2026 → Oct 2027 expected | acute myeloid leukemia | David Avigan | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02315118 | Dec 2014 → Dec 2017 | B-cell chronic lymphocytic leukemia | National University Hospital, Singapore | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-cell therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02315118 ↗ |
| Action | Deplete | “which mediates antibody-dependent cell cytotoxicity” NCT02315118 ↗ |
| Modality | Cell therapy | “autologous T-lymphocytes engineered to express a CD16-41BB-CD3zeta chimeric receptor” NCT02315118 ↗ |
| Route | Intravenous | “via intravenous (into the vein) infusion” NCT07374029 ↗ |